Frontiers in Psychiatry
November 13, 2023
Tor-Morten Kvam, Malin V Uthaug, Kristoffer A A Andersen et al.
21 citations
In a survey of 770 Norwegian adults who had a memorable experience with a classic psychedelic substance like psilocybin or LSD, most used the substance for recreational (46.1%) or therapeutic (42.3%) reasons. Psilocybin was the most common substance for the memorable experience. Many participants reported self-perceived symptoms of mental disorders and substance use disorders, and most said their condition improved after the experience. Adverse reactions were usually mild and short-lived, but 4.2% lasted a year or more, and 2.9% had persisting flashbacks for a year or more. The findings highlight both benefits and long-term risks in a self-selecting sample.
The British journal of psychiatry : the journal of mental science
July 11, 2025
Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
6 citations
In an open-label study of twelve adults with moderate to severe major depressive disorder, two sessions of MDMA-assisted therapy one month apart, combined with psychotherapy, led to a substantial average reduction of 19.3 points on the Montgomery-Asberg Depression Rating Scale and an average decrease of 11.7 points on the Sheehan Disability Scale, indicating improved daily functioning. No serious or unexpected adverse events occurred. The results suggest the approach is safe and feasible, with strong indications of efficacy, though randomized controlled trials are needed to confirm.
Journal of eating disorders
June 10, 2025
Camilla Lindvall Dahlgren, Elisabeth Tverrli, Lowan Han Stewart
3 citations
A female patient in her late twenties with anorexia nervosa and comorbid depression underwent a structured protocol of four ketamine-assisted psychotherapy sessions within an Acceptance and Commitment Therapy framework, followed by three ketamine booster treatments. Over a five-month follow-up, symptoms of eating disorder pathology, depression, and anxiety showed marked reduction after the initial sessions, a temporary increase during a therapy-free interval, then further decline and stabilization after boosters. Ketamine was well-tolerated with no new side effects. This case suggests that ketamine-assisted psychotherapy may produce rapid and sustained symptom remission for anorexia nervosa, though more research is needed across different patient groups and treatment protocols.